

July 23, 2014

Stock Rating
Equal-weight
Industry View
In-Line

Gilead Sciences Inc. HCV Still Near and LT Focus

Upside Sovaldi (+\$611M vs cons) drove a \$0.57 EPS beat: Sovaldi (+\$611M), Truvada (+\$18M), Viread (+\$24M) and Complera (+\$22M) drove the \$685M rev beat vs cons. Better gross margins (89% vs MSe 86%) and a lower tax rate (14.6% with a 1 qtr 3.6% catch-up) represented the majority of the delta between our \$2.14 and Gilead's reported EPS of \$2.36. Mgt. also gave 1st time guidance incorporating Sovaldi with revs of \$21-23B (prior \$11.3-11.5B). This suggests 2H Sovaldi revs of ~\$3.945-5.745B, below the 1H total of \$5.755B. Mgt. cited warehousing and inventory destocking ahead of the all-oral launch as potential contributing factors.

Sovaldi still the centerpiece: Near and long-term Sovaldi sales continue to dominate the debate. On the near-term, guidance seems to imply a seq. deceleration for 3Q followed by an uptick in 4Q after the all-oral launch, inline with our model. Hwr, with the implied 2H run-rate below 1H reported sales, it appears a modest disappointment vs high expectations. Nonetheless, sig. investor expectations for an early all-oral approval ahead of the 10/10 PDUFA (and the assoc sales bolus) is likely to offset any guidance concerns. While we agree early approval could represent 2014 upside, it could conversely make the 2015 comp that much harder. On the LT, our view remains that there are risks to sustainability of the HCV franchise. Separately, the early approval of idelalisib (CLL & iNHL) was a nice positive offset by the boxed warning and REMS. We still see it as a 10-15% mkt share drug with \$1B+ pot.

Capital allocation continues to represent the other LT driver, but mgt. isn't pointing to a deal: While mgt. repurchased 15.2M shares in the qtr (\$1.2B) and said it will finish another \$1.7B in buybacks by Sept., a near-term deal to ease LT Sovaldi tail concerns didn't appear imminent. We see continued investor focus on dividends and [REDACTED] as the cash from Sovaldi builds.

We expect a muted stock reaction even as Sovaldi delivered given high expectations: We believe cons expectations of a Sovaldi beat have been a major driver of GILD over the last few weeks, thus the beat was widely expected. With guidance not suggesting sig. upside to cons, we expect GILD to not move much tomorrow. Our 2014E/2015E EPS ests move modestly higher to \$8.17/\$9.19 (\$7.58/\$8.43 prior) on tax-rate, gross margin and share count changes to our model.

Key Ratios and Statistics

Reuters: GILD.O Bloomberg: GILD US
Biotechnology / United States of America

Shr price, close (Jul 23, 2014)	\$90.34
Mkt cap, curr (mm)	\$152,143
52-Week Range	\$90.74-55.96

Fiscal Year ending	12/13	12/14e	12/15e	12/16e
ModelWare EPS (\$)	2.05	8.16	9.19	10.17
Prior ModelWare EPS (\$)	-	7.58	8.42	9.64
P/E	36.7	11.1	9.8	8.9
Consensus EPS (\$)	1.98	6.73	8.22	9.35
Div yld (%)	0.0	-	0.5	1.2

Unless otherwise noted, all metrics are based on Morgan Stanley ModelWare framework (please see explanation later in this note).

\$ = Consensus data is provided by Thomson Reuters Estimates.

e = Morgan Stanley Research estimates

Morgan Stanley does and seeks to do business with companies covered in Morgan Stanley Research. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of Morgan Stanley Research. Investors should consider Morgan Stanley Research as only a single factor in making their investment decision.

For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report.

July 23, 2014
Gilead Sciences Inc.

Risk-Reward Snapshot: Gilead (GILD, EW, PT \$81)

Sovaldi peak and duration, HIV patent expirations drive Risk-Reward

Exhibit 1



Source: Morgan Stanley Research estimates, Thomson Reuters

Price Target \$81	We derive our PT from a discounted cash flow analysis that uses a WACC of 10% and a 2% terminal growth rate. The main drivers are the HIV franchise and Sovaldi.	
Bull Case \$145	DCF	The number of treated HCV patients do not decline post 2017E and competition is less robust; Gilead transitions more than half of HIV sales to new regimens. We assume: 1) ~35B in 2020E antiviral sales, of which \$16B is from HCV, 2) The number of naïve US HCV patients treated is stable at ~200k/yr, 3) HCV pricing is not impacted by competition, and 4) Complera/Eviplera/Stribild/TAF take ~60% patient share of HIV
Base Case \$81	DCF	US treated HCV patients decline modestly post 2017E, around half of HIV sales are transitioned to new regimens. We assume: 1) ~20B in 2020E antiviral sales, of which ~\$6B is from HCV, 2) The number of naïve US HCV patients treated declines to ~115k/yr, 3) HCV pricing is modestly impacted by competition (-15%), and 4) Complera/Eviplera/Stribild/TAF take ~35% patient share of HIV
Bear Case \$34	DCF	Rapid peak and then erosion of the HCV market, HIV cliffs: 1) ~9B in 2020E antiviral sales, of which ~\$500M is from HCV, 2) The number of naïve US HCV patients treated declines to baseline, 3) HCV pricing/share is aggressively impacted by competitors (-70%), 4) Complera/Eviplera/Stribild/TAF take ~20% patient share of HIV

Investment Thesis

We are EW Gilead as we believe some of the risks around HCV have been overlooked suggesting risk to out-year estimates. This is balanced by the potential for a solid hem/onc franchise in idelalisib and time to switch HIV patients away from therapies that go generic.

- **HCV (Sovaldi):** HCV demand is off to a strong start with sales likely of at least \$10B in the first year. That said, we don't have confidence that peak revenues will continue after all the patients in care are treated (~2017E). We highlight risks on multiple fronts including pricing, competition and high consensus expectations.

- **HIV:** Gilead has done a good job of switching naïve patients to the new STRs (Stribild and Complera), but Truvada/Atripla still hold ~60% of the market right now, which means a significant number still need to be switched. This is a potential source of LT risk. However, there is still time and we've yet to get all the TAF data.

- **Oncology (idelalisib):** We believe idelalisib can be a \$1-2B US asset. That said, duration of therapy is currently unclear (the major driver of sales) given the liver function issues. If LFTs cause short duration, there could be downside to sales. However, we note expectations are modest.

Risks to our price target

- 1) A longer peak to HCV sales, 2) A higher peak of HCV sales followed by a rapid decline, 3) Unexpected toxicity or competition in HCV, 4) Unexpected toxicity in idelalisib, 5) Early pipeline success for simtuzumab

July 23, 2014
Gilead Sciences Inc.

Exhibit 2

Gilead 2Q14 Variance

	MSe 2Q14E		2Q14A			Consensus		
	MSe	% Y/Y	Actual	% Y/Y	Difference	2Q14E*	Difference	%
Product Sales (WW):								
Atripla	\$923	-2%	\$871	-7%	-6%	\$875	(\$4)	0%
Truvada	\$807	0%	\$807	0%	0%	\$789	\$18	2%
Viread	\$269	8%	\$261	4%	-3%	\$237	\$24	10%
Complera/Eviplera	\$265	40%	\$299	59%	13%	\$277	\$22	8%
Stribild	\$248	150%	\$270	171%	9%	\$262	\$7	3%
Sovaldi	\$3,625	NM	\$3,481	NM	-4%	\$2,870	\$611	21%
Other	\$30	NM	\$24	-13%	-19%			
Total Antiviral Products	\$6,197	168%	\$6,012	160%	-3%			
Letairis	\$156	22%	\$145	13%	-7%	\$134	\$11	8%
Ranexa	\$129	21%	\$122	14%	-5%	\$119	\$3	2%
AmBisome	\$89	18%	\$95	26%	7%	\$87	\$7	8%
Cayston	\$40	18%	\$39	16%	-2%			
Other	\$1	-13%	\$0	NM	NM			
Total Product Sales	\$6,612	149%	\$6,413	141%	-3%	\$340	\$6,073	1784%
Royalty, Contract, Other Revs	\$93	-16%	\$122	11%	31%			
Total Revenues	\$6,705	142%	\$6,535	136%	-3%	\$5,850	\$685	12%
COGS	\$927	40%	\$723	9%	-22%			
Gross Profit	\$5,778	174%	\$5,812	176%	1%			
SG&A	\$575	18%	\$542	11%	-6%			
SG&A	\$535	42%	\$569	51%	6%			
Operating Income	\$4,668	276%	\$4,701	278%	1%			
Interest Expense, Net	(\$76)	NM	(\$102)	NM	34%			
Other Income (Expense), Net	(\$20)	NM	(\$4)	NM	-82%			
Pretax Income	\$4,572	293%	\$4,595	295%	1%			
Taxes	\$963	192%	\$671	104%	-30%			
Tax rate	21%	-26%	15%	-48%	-31%			
Net loss from noncontrolling interest	(\$5)	NM	(\$5)	NM	6%			
Net Income (Non-GAAP)	\$3,613	330%	\$3,930	368%	9%			
Non-GAAP EPS (excl. options)	\$2.14	331%	\$2.36	376%	11%	\$1.79	\$0.57	32%
GAAP EPS	\$1.96	331%	\$2.20	382%	12%			
Diluted Shares Outstanding	1678	-1%	1663	NM				
Gross Margin	86%	13%	89%	17%	3%	85%		
SG&A (% of Sales)	9%	-51%	8%	-53%	-3%			
SG&A (% of Sales)	8%	-41%	9%	-36%	9%			
Operating Margin	70%	55%	72%	60%	3%			

Source: Company Data, Morgan Stanley Research

July 23, 2014

Gilead Sciences Inc.

Exhibit 3

Gilead Income Statement

	2009	2010	2011	2012	2013	1Q14A	2Q14A	3Q14E	4Q14E	2014E	2015E	2016E	2017E	2018E	2019E	2020E
Gilead Income Statement																
Product Sales	6,469	7,390	8,102	9,398	10,804	4,871	6,413	5,796	7,672	24,813	27,797	29,280	26,763	25,286	22,933	22,660
Royalty, contract and other revenues	542	559	263	304	398	128	122	71	43	365	377	390	403	418	433	448
Total Revenue	7,011	7,949	8,365	9,703	11,202	4,999	6,535	5,867	7,716	25,178	28,174	29,670	27,166	25,703	23,366	23,109
						Co. Guidance				\$21-23B						
Consensus Revenue						6,530	6,257	22,629	26,189	28,161	30,609					
COGS	1,530	1,793	2,046	2,401	2,708	611	723	964	1,233	3,532	4,679	4,909	4,647	4,544	4,434	4,491
Gross Profit	5,481	6,157	6,339	7,302	8,493	4,388	5,812	4,903	6,482	21,646	23,495	24,761	22,519	21,159	18,932	18,618
						831	839	1,119	1,496	1,948	558	542	600	650	2,350	2,515
						Co. Guidance				\$2-3-2.4B	2,691	2,825	2,896	2,968	3,042	3,042
SG&A	820	913	1,094	1,226	1,557	500	569	610	671	2,350	2,703	2,973	3,121	3,090	3,059	3,029
						Co. Guidance				\$2-3-2.4B						
Operating Income	3,830	4,405	4,126	4,580	4,988	3,330	4,701	3,693	5,161	16,946	18,278	19,098	16,572	15,173	12,904	12,547
Interest expense	-70	-109	-182	-354	-307	-76	-102	-102	-82	-363	-400	-383	-364	-343	-343	-332
Other income (expense), net	42	60	67	-37	-9	-20	-4	-4	57	30	123	239	325	371	376	356
Pretax Income	3,803	4,357	4,011	4,189	4,673	3,234	4,595	3,587	5,136	16,614	18,000	18,954	16,534	15,202	12,938	12,571
Taxes	950	1,154	987	1,123	1,240	751	671	635	883	3,020	2,732	2,308	1,848	1,851	1,705	1,782
Tax Rate	25%	26%	25%	27%	27%	23%	15%	18%	17%	18.2%	15%	12%	11%	12%	13%	14%
						Co. Guidance				17.5-20.5%						
Net income (non-gaap)	2,853	3,203	3,024	3,066	3,433	2,483	3,924	2,952	4,253	13,594	15,268	16,645	14,686	13,350	11,233	10,789
Net loss from noncontrolling interest	-10	-12	-15	-18	-18	-5	-5	-5	-2	-18	-18	-18	0	0	0	0
Net income to Gilead (Non-GAAP)	2,863	3,214	3,039	3,084	3,451	2,488	3,930	2,957	4,255	13,611	15,286	16,663	14,686	13,350	11,233	10,789
Non-GAAP EPS (excl. options)	\$1.53	\$1.84	\$1.93	\$1.95	\$2.05	\$1.48	\$2.36	\$1.78	\$2.56	\$8.17	\$9.19	\$10.18	\$9.32	\$8.96	\$8.05	\$8.30
Consensus EPS						1.62	1.94	6.73	8.22	9.35	10.79					
Non-gaap EPS (incl. options)	\$1.46	\$1.76	\$1.84	\$1.73	\$1.94	\$1.44	\$2.32	\$1.74	\$2.53	\$8.01	\$8.98	\$9.94	\$9.05	\$8.65	\$7.68	\$7.87
GAAP EPS (incl. options)	\$1.41	\$1.66	\$1.77	\$1.64	\$1.82	\$1.32	\$2.20	\$1.60	\$2.89	\$7.97	\$8.98	\$9.94	\$9.05	\$8.64	\$7.68	\$7.86
Basic Shares - GAAP	1,809	1,712	1,515	1,515	1,529	1,537	1,533	1,532	1,531	1,526	1,523	1,499	1,443	1,365	1,278	1,190
Diluted Shares - GAAP	1,868	1,747	1,580	1,583	1,686	1,680	1,664	1,663	1,662	1,667	1,664	1,638	1,576	1,491	1,397	1,300
Diluted Shares - non-GAAP	1,868	1,743	1,576	1,580	1,685	1,679	1,663	1,662	1,661	1,666	1,663	1,637	1,576	1,490	1,396	1,300
Margin Analysis (Non-GAAP)																
COGS (product revenue)	24%	24%	25%	26%	25%	13%	11%	24%	26%	25%	25%	25%	25%	25%	25%	25%
Gross Margin (total revenue)	78%	77%	76%	75%	76%	88%	89%	84%	84%	86%	83%	83%	83%	82%	81%	81%
						Co. Guidance				85-88%						
SG&A (as a % of sales)	12%	11%	13%	13%	14%	10%	9%	14%	15%	14%	14%	14%	14%	14%	14%	14%
SG&A (as a % of sales)	12%	11%	13%	15%	17%	11%	8%	18%	16%	17%	17%	17%	17%	17%	17%	17%
Operating Margin	55%	55%	49%	47%	45%	67%	72%	63%	67%	67%	65%	64%	61%	59%	55%	54%
EBITDA Margin	58%	59%	53%	50%	48%	69%	73%	65%	68%	69%	66%	66%	63%	61%	58%	57%
Net Margin	41%	40%	36%	32%	31%	50%	60%	50%	55%	54%	54%	56%	54%	52%	48%	47%
Growth Analysis (Non-GAAP)																
Net product sales	27%	14%	10%	16%	15%	104%	141%	114%	152%	130%	12%	5%	-9%	-6%	-9%	-1%
Total revenue	31%	13%	5%	16%	15%	97%	136%	111%	147%	125%	12%	5%	-8%	-5%	-9%	-1%
COGS	37%	17%	14%	17%	13%	0%	9%	46%	59%	30%	32%	5%	-5%	-2%	-2%	1%
SG&A	27%	1%	33%	34%	30%	21%	11%	23%	27%	21%	7%	7%	5%	2%	2%	2%
Operating margin (EBIT)	14%	11%	20%	12%	27%	50%	51%	62%	42%	51%	15%	10%	5%	-1%	-1%	-1%
Operating margin (EBIT)	3%	1%	-11%	-4%	-6%	50%	60%	39%	53%	51%	-4%	-1%	-5%	-3%	-6%	-2%
EBITDA margin	3%	2%	-10%	-5%	-5%	43%	53%	34%	47%	45%	-4%	-1%	-5%	-3%	-5%	-1%

Source: Company Data, Morgan Stanley Research

July 23, 2014

Gilead Sciences Inc.

Exhibit 4

Gilead Product Revenues (1 of 2)

Product Revenue	2009A	2010A	2011A	2012A	2013A	2014E				2015E	2016E	2017E	2018E	2019E	2020E	
						1Q14	2Q14	3Q14E	4Q14E							
Atripla	2,382	2,927	3,225	3,574	3,648	780	871	917	1,009	3,577	3,572	3,559	3,505	3,331	2,741	2,534
US (2021 Expiration)	1,646	1,909	2,022	2,253	2,356	490	578	610	678	2,356	2,447	2,507	2,505	2,503	2,500	2,497
EU (2018 Expiration)	678	910	1,043	1,103	1,062	237	234	237	270	978	869	782	717	573	177	20
ROW	59	108	160	219	231	53	58	71	61	243	256	269	283	255	64	16
Truvada	2,490	2,650	2,875	3,181	3,136	760	807	803	799	3,169	3,140	3,125	3,124	2,779	2,139	1,892
US (2021 Expiration)	1,178	1,309	1,385	1,613	1,570	368	400	430	448	1,645	1,679	1,711	1,742	1,771	1,797	1,822
EU (2018 Expiration)	1,170	1,171	1,257	1,316	1,296	323	338	300	278	1,240	1,163	1,101	1,054	844	259	29
ROW	142	170	232	253	270	69	69	73	73	284	298	313	328	164	82	41
Viread	668	732	738	849	959	211	261	249	294	1,014	1,064	1,113	1,166	822	241	29
US (2018 Expiration, Teva settlement)	290	320	325	388	428	81	117	115	121	433	432	430	425	304	81	8
EU (2018 Expiration)	273	293	328	336	354	84	88	93	117	382	408	430	454	318	100	15
ROW	105	119	85	125	177	46	57	41	56	199	224	253	286	200	60	6
Complera/Eviplera			39	342	809	251	299	310	352	1,212	1,688	2,292	2,504	2,701	2,818	2,943
US (2023 Expiration)			39	280	503	130	154	195	237	717	1,043	1,453	1,566	1,673	1,788	1,910
EU (2022 Expiration)			0	53	268	109	132	100	97	438	569	749	834	914	910	912
ROW			0	9	39	11	13	15	19	58	75	91	104	115	120	120
Stribild				58	539	215	270	289	315	1,090	1,917	2,787	3,345	3,853	4,132	4,418
US (2029 Expiration)				58	510	187	229	223	206	846	1,330	1,820	2,111	2,346	2,596	2,862
EU (2027 Expiration)					24	24	31	51	102	208	534	898	1,154	1,416	1,430	1,445
ROW				0	5	5	9	15	7	36	53	69	80	92	105	111
TAF												474	998	1,372	1,800	1,995
US (2022/2029 Expiration)												446	834	1,072	1,328	1,407
EU (2021/2027 Expiration)												23	129	248	404	510
ROW												5	35	53	68	78
Sovaldi					139	2,274	3,481	2,765	4,374	12,894	14,073	13,649	10,045	8,471	7,219	7,016
US (2029 Expiration, 2030 for FDC)					136	2,098	3,032	2,100	3,590	10,819	9,212	7,394	5,247	4,645	4,041	3,933
EU (2028 Expiration, 2029 for FDC)					3	164	401	600	680	1,845	3,559	4,240	2,750	2,076	1,519	1,302
ROW					0	13	49	65	104	231	1,302	2,015	2,047	1,750	1,659	1,782
Other Antiviral	300	228	173	138	109	18	24	25	55	123	152	164	193	237	266	301
Cobicistat/Tyboost (2027 Expiration)								10	15	25	100	125	150	165	180	195
Total Antiviral Products	5,839	6,537	7,050	8,142	9,340	4,508	6,012	5,369	7,214	23,104	25,706	26,813	24,032	22,359	19,736	19,328

Source: Company Data, Morgan Stanley Research

Exhibit 5

Gilead Product Revenues (2 of 2)

Product Revenue	2009A	2010A	2011A	2012A	2013A	2014E				2015E	2016E	2017E	2018E	2019E	2020E
						1Q14	2Q14	3Q14E	4Q14E						
Letairis (US Only - Patent Expiration 2018)	184	240	293	410	520	123	145	156	156	624	718	789	852	639	64
Ranexa (US Only - Patent Expiration 2019)	131	240	320	373	449	112	122	129	129	516	593	682	771	856	700
AmBisome (US Patent 2016 / EU 2008)	299	306	330	347	352	92	95	89	89	355	359	305	153	15	0
Other Products	17	67	109	127	143	36	39	53	84	214	422	690	955	1,416	2,569
Cayston (US & EU Patents 2021)		48	91	107	139	36	39	42	44	161	185	207	228	246	271
Other	17	19	18	20	4	0	0	1	1	4	4	4	4	4	4
Idelalisib (2025 Expiration)								10	39	49	233	479	723	1,166	2,294
Total Product Sales	6,469	7,390	8,102	9,398	10,804	4,871	6,413	5,796	7,672	24,813	27,797	29,280	26,763	25,286	22,660
Royalty, contract and other revenue	542	559	283	304	398	128	122	71	43	365	377	390	403	418	448
Royalty Revenue	492	546	269	291	384	124	118	68	40	351	363	376	389	404	434
Tamiflu Royalties	393	387	76	44	135	52	58	5	-25	90	90	90	90	90	90
Other Royalties	99	159	193	247	249	72	60	63	65	261	273	286	300	314	345
Contract and other revenue	50	14	14	14	14	4	4	3	3	14	14	14	14	14	14
Total Revenues	7,011	7,949	8,385	9,703	11,202	4,999	6,535	5,867	7,716	25,178	28,174	29,670	27,166	25,703	23,109

Source: Company Data, Morgan Stanley Research

July 23, 2014

Gilead Sciences Inc.

Exhibit 6

Gilead Balance Sheet

	2009	2010	2011	2012	2013	2014E	2015E	2016E	2017E	2018E	2019E	2020E
Current assets												
Cash and Equivalents	1,273	908	9,884	1,804	2,113	10,875	21,989	30,255	34,444	34,626	32,346	27,517
Marketable Securities	384	1,191	16	59	19	530	989	1,403	1,776	2,111	2,413	2,684
Trade Receivables, net	1,390	1,622	1,951	1,751	2,100	4,721	5,282	5,563	5,094	4,819	4,381	4,333
Inventories	1,052	1,204	1,390	1,745	2,056	2,681	3,552	3,726	3,528	3,449	3,366	3,409
Deferred Taxes, Net	295	279	208	263	331	331	331	331	331	331	331	331
Prepaid Expenses & Taxes	352	388	342	535	564	1,385	1,409	1,483	1,358	1,285	1,168	1,155
Other Current Assets	67	116	127	0	92	378	394	415	380	386	350	347
Total current assets	4,813	5,708	13,919	6,156	7,274	20,899	33,947	43,177	46,910	47,006	44,354	39,775
Property, Plant & Equipment, Net	700	701	774	1,100	1,166	1,521	1,960	2,455	2,904	3,324	3,680	4,029
Non-Current Portion of Prepaid Royalties	226	204	175	176	199	225	254	287	325	367	415	470
Non-Current Deferred Tax Asset	101	153	144	131	155	155	155	155	155	155	155	155
Intangible Assets, net	1,062	893	2,067	11,736	11,900	11,658	11,416	11,174	10,932	10,690	10,448	10,206
Long Term Marketable Securities	2,248	3,219	64	720	439	439	439	439	439	439	439	439
Goodwill	463	533	0	1,061	1,169	1,169	1,169	1,169	1,169	1,169	1,169	1,169
Other Assets	86	181	161	159	195	413	435	428	392	371	374	370
Total assets	9,699	11,593	17,303	21,240	22,497	36,479	49,774	59,284	63,225	63,521	61,034	56,612
Current liabilities												
Accounts Payable	811	803	1,206	1,327	1,256	1,638	2,170	2,276	2,155	2,107	2,056	2,082
Accrued Expenses/Comp & Employee Ben.	132	148	173	237	244	547	613	645	591	559	508	502
Accrued Liabilities	800	765	1,059	1,433	2,018	1,880	1,826	1,982	2,081	2,095	2,110	2,125
Deferred Revenue	123	103	75	103	111	111	111	111	111	111	111	111
Current Portion of Long Term Debt	6	646	2	1,169	2,697	0	1,167	0	0	0	0	0
Total current liabilities	1,872	2,465	2,515	4,270	6,325	4,176	5,885	5,014	4,938	4,872	4,784	4,820
Deferred Tax Liabilities	87	107	136	116	162	162	162	162	162	162	162	162
Long-Term Debt	1,155	2,839	7,606	7,055	3,939	9,821	7,932	7,932	7,232	7,232	7,232	6,733
Long-Term Deferred Revenue	43	33	32	21	22	22	22	22	22	22	22	22
Other long-term obligations	36	27	148	228	304	904	904	904	904	904	904	904
Total liabilities	3,193	5,471	10,436	11,689	10,752	15,085	14,905	14,034	13,258	13,192	13,105	12,642
Minority Interest	138	258	128	241	375	358	340	323	323	323	323	323
Preferred Stock	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock	1	1	1	1	2	2	2	2	2	2	2	2
Additional paid-in capital	4,377	4,648	4,903	5,650	5,387	4,870	4,172	-82	-7,488	-17,435	-28,411	-40,551
(Accumulated Deficit) Retained Earnings	1,995	1,184	1,777	3,705	6,105	16,289	30,479	45,132	57,255	67,564	76,141	84,322
Accumulated Other Comprehensive Income	-6	31	58	-46	-124	-124	-124	-124	-124	-124	-124	-124
Total stockholders' equity	6,367	5,864	6,739	9,310	11,369	21,036	34,528	44,927	49,644	50,006	47,606	43,648
Total Liabilities and equity	9,699	11,593	17,303	21,240	22,497	36,479	49,774	59,284	63,225	63,521	61,034	56,612

Source: Company Data, Morgan Stanley Research

July 23, 2014

Gilead Sciences Inc.

Exhibit 7

Gilead Cash Flow Statement

	2009	2010	2011	2012	2013	2014E	2015E	2016E	2017E	2018E	2019E	2020E
Net Income (Loss)	2,626	2,890	2,789	2,574	3,057	13,276	14,919	16,261	14,263	12,886	10,722	10,226
Depreciation & Amortization	213	265	302	278	345	379	423	475	527	581	634	691
Stock-based compensation expense	100	118	152	209	252	318	349	384	423	465	511	563
In-process research and development impairment charges		136	27	0	0	0	0	0	0	0	0	0
Tax Benefits Related to Employee Stock Options	88	82	37	-2	6							
Deferred Income Taxes	-42	12	64	-39	-98	0	0	0	0	0	0	0
Amortization of Bond Discount					0	26	27	0	0	0	0	0
Other	64	10	48	-2	106							
Changes in operating assets and liabilities:												
Accounts receivable, net	-356	-349	-376	198	-315	-2,620	-562	-280	469	274	438	48
Inventories	-75	-161	-201	-350	-343	-625	-871	-174	198	78	84	-43
Prepaid Expenses	-66	-70	-14	-129	-170	-1,133	-70	-129	123	25	104	-38
Accounts Payable	204	-4	429	117	-98	382	532	107	-121	-48	-51	26
Accrued Liabilities and taxes payable	275	-66	411	318	342	166	11	189	45	-18	-36	10
Deferred Revenue	49	-30	-29	23	22	0	0	0	0	0	0	0
Net cash provided by (used in) operating activities	3,080	2,834	3,639	3,195	3,105	10,168	14,759	16,832	15,927	14,244	12,406	11,483
Purchases Of Marketable Securities	-2,614	-5,503	-5,128	-1,245	-257	-5,128	-5,128	-5,128	-5,128	-5,128	-5,128	-5,128
Proceeds From Sales Of Marketable Securities	1,441	3,034	8,650	528	494	4,615	4,615	4,615	4,615	4,615	4,615	4,615
Proceeds From Maturities Of Marketable Securities	436	684	788	45	78	2	53	99	140	178	211	241
Acquisitions, Net Of Cash	-1,248	-91	-589	-10,752	-379	0	0	0	0	0	0	0
Purchases of PP&E	-230	-62	-132	-397	-191	-492	-621	-728	-734	-759	-748	-798
Other				-25	0	-218	-21	7	36	21	-3	4
Net cash used in investing activities	-2,216	-1,938	3,590	-11,846	-254	-1,221	-1,102	-1,135	-1,071	-1,073	-1,053	-1,065
Cash Flows from Financing Activities												
Proceeds from issuances of common stock (for ESO)	223	221	212	466	313	204	164	132	106	85	68	33
Excess tax benefits from stock-based compensation	80	82	41	114	279	162	108	70	51	45	39	20
Proceeds from sale of/(payments to settle) warrants		155			-1,040							
Proceeds/(purchases) of convertible note hedges		-363		214	2,774							
Proceeds from/(repayments of) debt financing	-311	2,457	4,009	305	-4,440	3,759	-750	-1,167	-699	0	0	-499
Contributions from (distributions to) noncontrolling interest	-45	132	-115	131	152							
Repurchases of common stock	-998	-4,023	-2,383	-667	-582	-1,200	-1,320	-4,840	-7,986	-10,542	-11,596	-12,755
Dividends paid					0	-746	-1,626	-2,139	-2,577	-2,144	-2,045	
Other					0	-3,110	0	0	0	0	0	0
Net cash provided by financing activities	-1,051	-1,339	1,764	563	-2,544	-185	-2,543	-7,431	-10,668	-12,989	-13,633	-15,246
Effect of Exchange Rate Changes on Cash	1	77	-17	8	2							
Change in cash	-186	-365	8,976	-8,080	309	8,762	11,114	8,266	4,189	182	-2,280	-4,829
Cash at beginning of year	1,459	1,273	908	9,884	1,804	2,113	10,875	21,989	30,255	34,444	34,626	32,346
Cash at end of year	1,273	908	9,884	1,804	2,113	10,875	21,989	30,255	34,444	34,626	32,346	27,517

Source: Company Data, Morgan Stanley Research



Morgan Stanley ModelWare is a proprietary analytic framework that helps clients uncover value, adjusting for distortions and ambiguities created by local accounting regulations. For example, ModelWare EPS adjusts for one-time events, capitalizes operating leases (where their use is significant), and converts inventory from LIFO costing to a FIFO basis. ModelWare also emphasizes the separation of operating performance of a company from its financing for a more complete view of how a company generates earnings.

Disclosure Section

The information and opinions in Morgan Stanley Research were prepared by Morgan Stanley & Co. LLC, and/or Morgan Stanley [REDACTED] S.A., and/or Morgan Stanley Mexico, Casa de Bolsa, S.A. de C.V., and/or Morgan Stanley Canada Limited. As used in this disclosure section, "Morgan Stanley" includes Morgan Stanley & Co. LLC, Morgan Stanley [REDACTED] S.A., Morgan Stanley Mexico, Casa de Bolsa, S.A. de C.V., Morgan Stanley Canada Limited and their affiliates as necessary. For important disclosures, stock price charts and equity rating histories regarding companies that are the subject of this report, please see the Morgan Stanley Research Disclosure Website at [REDACTED] or contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY, 10036 USA. For valuation methodology and risks associated with any price targets referenced in this research report, please contact the Client Support Team as follows: US/Canada +1 800 303-2495; Hong Kong +852 2848-5999; Latin America +1 718 754-5444 (U.S.); London +44 (0)20-7425-8169; Singapore +65 6834-6860; Sydney +61 (0)2-9770-1505; Tokyo +81 (0)3-6836-9000. Alternatively you may contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY 10036 USA.

Analyst Certification

The following analysts hereby certify that their views about the companies and their securities discussed in this report are accurately expressed and that they have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report: Matthew Harrison.

Unless otherwise stated, the individuals listed on the cover page of this report are research analysts.

Global Research Conflict Management Policy

Morgan Stanley Research has been published in accordance with our conflict management policy, which is available at [REDACTED]

Important US Regulatory Disclosures on Subject Companies

As of June 30, 2014, Morgan Stanley beneficially owned 1% or more of a class of common equity securities of the following companies covered in Morgan Stanley Research: Akebia Therapeutics Inc., Alnylam Pharmaceuticals, AMAG Pharmaceuticals, Inc., Auxilium Pharmaceuticals, Inc., Cubist Pharmaceuticals Inc., GW Pharmaceuticals PLC, Idenix Pharmaceuticals, Inc., ImmunoGen Inc., Ironwood Pharmaceuticals, Inc., Ophthotech Corp. Within the last 12 months, Morgan Stanley managed or co-managed a public offering (or 144A offering) of securities of Akebia Therapeutics Inc., AMAG Pharmaceuticals, Inc., Amgen Inc., Celgene Corp., Chimerix Inc., Cubist Pharmaceuticals Inc., Gilead Sciences Inc., GW Pharmaceuticals PLC, Ironwood Pharmaceuticals, Inc., Ophthotech Corp., Portola Pharmaceuticals Inc., Relypsa, Inc., Synageva Biopharma Corp., Ultragenyx Pharmaceutical Inc., Versartis, Inc..

Within the last 12 months, Morgan Stanley has received compensation for investment banking services from Akebia Therapeutics Inc., AMAG Pharmaceuticals, Inc., Amgen Inc., Biogen Idec Inc., Celgene Corp., Chimerix Inc., Cubist Pharmaceuticals Inc., Gilead Sciences Inc., GW Pharmaceuticals PLC, Ironwood Pharmaceuticals, Inc., Ophthotech Corp., Portola Pharmaceuticals Inc., Relypsa, Inc., Synageva Biopharma Corp., Theravance Inc., Ultragenyx Pharmaceutical Inc., Versartis, Inc..

In the next 3 months, Morgan Stanley expects to receive or intends to seek compensation for investment banking services from Akebia Therapeutics Inc., Alexion Pharmaceuticals, Alnylam Pharmaceuticals, AMAG Pharmaceuticals, Inc., Amgen Inc., Auxilium Pharmaceuticals, Biogen Idec Inc., Celgene Corp., Chimerix Inc., Cubist Pharmaceuticals Inc., Gilead Sciences Inc., GW Pharmaceuticals PLC, ImmunoGen Inc., Incyte Corporation, Infinity Pharmaceuticals Inc., InterMune, Ironwood Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Inc., Neurocrine Biosciences Inc., NPS Pharmaceuticals, Ophthotech Corp., Portola Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc., Relypsa, Inc., Synageva Biopharma Corp., Theravance Inc., Ultragenyx Pharmaceutical Inc., Versartis, Inc., Vertex Pharmaceuticals, XenoPort Inc.

Within the last 12 months, Morgan Stanley has received compensation for products and services other than investment banking services from Amgen Inc., Auxilium Pharmaceuticals, Biogen Idec Inc., Celgene Corp., Cubist Pharmaceuticals Inc., Vertex Pharmaceuticals.

Within the last 12 months, Morgan Stanley has provided or is providing investment banking services to, or has an investment banking client relationship with, the following company: Akebia Therapeutics Inc., Alexion Pharmaceuticals, Alnylam Pharmaceuticals, AMAG Pharmaceuticals, Inc., Amgen Inc., Auxilium Pharmaceuticals, Biogen Idec Inc., Celgene Corp., Chimerix Inc., Cubist Pharmaceuticals Inc., Gilead Sciences Inc., GW Pharmaceuticals PLC, ImmunoGen Inc., Incyte Corporation, Infinity Pharmaceuticals Inc., InterMune, Ironwood Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Inc., Neurocrine Biosciences Inc., NPS Pharmaceuticals, Ophthotech Corp., Portola Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc., Relypsa, Inc., Synageva Biopharma Corp., Theravance Inc., Ultragenyx Pharmaceutical Inc., Versartis, Inc., Vertex Pharmaceuticals, XenoPort Inc.

Within the last 12 months, Morgan Stanley has either provided or is providing non-investment banking, securities-related services to and/or in the past has entered into an agreement to provide services or has a client relationship with the following company: AMAG Pharmaceuticals, Inc., Amgen Inc., Auxilium Pharmaceuticals, Biogen Idec Inc., Celgene Corp., Cubist Pharmaceuticals Inc., Gilead Sciences Inc., InterMune, Portola Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc., Vertex Pharmaceuticals.

Morgan Stanley & Co. LLC makes a market in the securities of Akebia Therapeutics Inc., Alexion Pharmaceuticals, Alnylam Pharmaceuticals, AMAG Pharmaceuticals, Inc., Amgen Inc., Auxilium Pharmaceuticals, Biogen Idec Inc., Celgene Corp., Chimerix Inc., Cubist Pharmaceuticals Inc., Gilead Sciences Inc., Idenix Pharmaceuticals, Inc., ImmunoGen Inc., Incyte Corporation, Infinity Pharmaceuticals Inc., InterMune, Ironwood Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Inc., Neurocrine Biosciences Inc., NPS Pharmaceuticals, Ophthotech Corp., Portola Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc., Relypsa, Inc., Synageva Biopharma Corp., Theravance Inc., Versartis, Inc., Vertex Pharmaceuticals, XenoPort Inc.

The equity research analysts or strategists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors, firm revenues and overall investment banking revenues.

Morgan Stanley and its affiliates do business that relates to companies/instruments covered in Morgan Stanley Research, including market making, providing liquidity and specialized trading, risk arbitrage and other proprietary trading, fund management, commercial banking, extension of credit, investment services and investment banking. Morgan Stanley sells to and buys from customers the securities/instruments of companies covered in Morgan Stanley Research on a principal basis. Morgan Stanley may have a position in the debt of the Company or instruments discussed in this report.

Certain disclosures listed above are also for compliance with applicable regulations in non-US jurisdictions.

STOCK RATINGS

Morgan Stanley uses a relative rating system using terms such as Overweight, Equal-weight, Not-Rated or Underweight (see definitions below). Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold and sell. Investors should carefully read the definitions of all ratings used in Morgan Stanley Research. In addition, since Morgan Stanley Research contains more complete information concerning the analyst's views, investors should carefully read Morgan Stanley Research, in its entirety, and not infer the contents from the rating alone. In any case, ratings (or research) should not be used or relied upon as investment advice. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations.

Global Stock Ratings Distribution

(as of June 30, 2014)

For disclosure purposes only (in accordance with NASD and NYSE requirements), we include the category headings of Buy, Hold, and Sell alongside our ratings of Overweight, Equal-weight, Not-Rated and Underweight. Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold, and sell but represent recommended relative weightings (see definitions below). To satisfy regulatory requirements, we correspond Overweight, our most positive stock rating, with a buy recommendation; we correspond Equal-weight and Not-Rated to hold and Underweight to sell recommendations, respectively.

Stock Rating Category	Coverage Universe		Investment Banking Clients (IBC)		
	Count	% of Total	Count	% of Total IBC	% of Rating Category
Overweight/Buy	1080	35%	367	38%	34%
Equal-weight/Hold	1339	44%	469	49%	35%
Not-Rated/Hold	113	4%	23	2%	20%
Underweight/Sell	546	18%	98	10%	18%
Total	3,078		957		

Data include common stock and ADRs currently assigned ratings. Investment Banking Clients are companies from whom Morgan Stanley received investment banking compensation in the last 12 months.

Analyst Stock Ratings

Overweight (O). The stock's total return is expected to exceed the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Equal-weight (E). The stock's total return is expected to be in line with the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Not-Rated (NR). Currently the analyst does not have adequate conviction about the stock's total return relative to the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Underweight (U). The stock's total return is expected to be below the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Unless otherwise specified, the time frame for price targets included in Morgan Stanley Research is 12 to 18 months.

Analyst Industry Views

Attractive (A): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be attractive vs. the relevant broad market benchmark, as indicated below.

In-Line (I): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be in line with the relevant broad market benchmark, as indicated below.


Cautious (C): The analyst views the performance of his or her industry coverage universe over the next 12-18 months with caution vs. the relevant broad market benchmark, as indicated below.

Benchmarks for each region are as follows: North America - S&P 500; Latin America - relevant MSCI country index or MSCI Latin America Index; Europe - MSCI Europe; Japan - TOPIX; Asia - relevant MSCI country index or MSCI sub-regional index or MSCI AC Asia Pacific ex Japan Index.

Stock Price, Price Target and Rating History (See Rating Definitions)

July 23, 2014

Gilead Sciences Inc.

Gilead Sciences Inc. (GILD.O) - As of 7/23/14 in USD
Industry : Biotechnology

Source: Morgan Stanley Research Date Format : MM/DD/YY Price Target -- No Price Target Assigned (NA)
 Stock Price (Not Covered by Current Analyst) — Stock Price (Covered by Current Analyst) —
 Stock and Industry Ratings (abbreviations below) appear as ♦ Stock Rating/Industry View
 Stock Ratings: Overweight (O) Equal-weight (E) Underweight (U) Not-Rated (NR) No Rating Available (NA)
 Industry View: Attractive (A) In-line (I) Cautious (C) No Rating (NR)

Effective January 13, 2014, the stocks covered by Morgan Stanley Asia Pacific will be rated relative to the analyst's industry (or industry team's) coverage.

Effective January 13, 2014, the industry view benchmarks for Morgan Stanley Asia Pacific are as follows: relevant MSCI country index or MSCI sub-regional index or MSCI AC Asia Pacific ex Japan Index.

Important Disclosures for Morgan Stanley Smith Barney LLC Customers

Important disclosures regarding the relationship between the companies that are the subject of Morgan Stanley Research and Morgan Stanley Smith Barney LLC or Morgan Stanley or any of their affiliates, are available on the Morgan Stanley Wealth Management disclosure website at [www.morganstanley.com/disclosure](#).

For Morgan Stanley specific disclosures, you may refer to [www.morganstanley.com/disclosure](#).

Each Morgan Stanley Equity Research report is reviewed and approved on behalf of Morgan Stanley Smith Barney LLC. This review and approval is conducted by the same person who reviews the Equity Research report on behalf of Morgan Stanley. This could create a conflict of interest.

Other Important Disclosures

Morgan Stanley & Co. International PLC and its affiliates have a significant financial interest in the debt securities of Amgen Inc., Celgene Corp, Cubist Pharmaceuticals Inc., **Gilead Sciences Inc.**

Morgan Stanley is not acting as a municipal advisor and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of Section 975 of the Dodd-Frank Wall Street Reform and Consumer Protection Act.

Morgan Stanley produces an equity research product called a "Tactical Idea." Views contained in a "Tactical Idea" on a particular stock may be contrary to the recommendations or views expressed in research on the same stock. This may be the result of differing time horizons, methodologies, market events, or other factors. For all research available on a particular stock, please contact your sales representative or go to Matrix at [www.morganstanley.com/matrix](#).

Morgan Stanley Research is provided to our clients through our proprietary research portal on Matrix and also distributed electronically by Morgan Stanley to clients. Certain, but not all, Morgan Stanley Research products are also made available to clients through third-party vendors or redistributed to clients through alternate electronic means as a convenience. For access to all available Morgan Stanley Research, please contact your sales representative or go to Matrix at [www.morganstanley.com/matrix](#).

Any access and/or use of Morgan Stanley Research is subject to Morgan Stanley's Terms of Use ([www.morganstanley.com/terms](#)). By accessing and/or using Morgan Stanley Research, you are indicating that you have read and agree to be bound by our Terms of Use ([www.morganstanley.com/terms](#)). In addition you consent to Morgan Stanley processing your personal data and using cookies in accordance with our Privacy Policy and our Global Cookies Policy ([www.morganstanley.com/privacy](#)), including for the purposes of setting your preferences and to collect readership data so that we can deliver better and more personalized service and products to you. To find out more information about how Morgan Stanley processes personal data, how we use cookies and how to reject cookies see our Privacy Policy and our Global Cookies Policy ([www.morganstanley.com/privacy](#)).

If you do not agree to our Terms of Use and/or if you do not wish to provide your consent to Morgan Stanley processing your personal data or using cookies please do not access our research.

Morgan Stanley Research does not provide individually tailored investment advice. Morgan Stanley Research has been prepared without regard to the circumstances and objectives of those who receive it. Morgan Stanley recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. The appropriateness of an investment or strategy will depend on an investor's circumstances and objectives. The securities, instruments, or strategies discussed in Morgan Stanley Research may not be suitable for all investors, and certain investors may not be eligible to purchase or participate in some or all of them. Morgan Stanley Research is not an offer to buy or sell or the solicitation of an offer to buy or sell any security/instrument or to participate in any particular trading strategy. The value of and income from your investments may vary because of changes in interest rates, foreign exchange rates, default rates, prepayment rates, securities/instruments prices, market indexes, operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in securities/instruments transactions. Past performance is not necessarily a guide to future performance. Estimates

of future performance are based on assumptions that may not be realized. If provided, and unless otherwise stated, the closing price on the cover page is that of the primary exchange for the subject company's securities/instruments.

The fixed income research analysts, strategists or economists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality, accuracy and value of research, firm profitability or revenues (which include fixed income trading and capital markets profitability or revenues), client feedback and competitive factors. Fixed Income Research analysts', strategists' or economists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.

The "Important US Regulatory Disclosures on Subject Companies" section in Morgan Stanley Research lists all companies mentioned where Morgan Stanley owns 1% or more of a class of common equity securities of the companies. For all other companies mentioned in Morgan Stanley Research, Morgan Stanley may have an investment of less than 1% in securities/instruments or derivatives of securities/instruments of companies and may trade them in ways different from those discussed in Morgan Stanley Research. Employees of Morgan Stanley not involved in the preparation of Morgan Stanley Research may have investments in securities/instruments or derivatives of securities/instruments of companies mentioned and may trade them in ways different from those discussed in Morgan Stanley Research. Derivatives may be issued by Morgan Stanley or associated persons.

With the exception of information regarding Morgan Stanley, Morgan Stanley Research is based on public information. Morgan Stanley makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete. We have no obligation to tell you when opinions or information in Morgan Stanley Research change apart from when we intend to discontinue equity research coverage of a subject company. Facts and views presented in Morgan Stanley Research have not been reviewed by, and may not reflect information known to, professionals in other Morgan Stanley business areas, including investment banking personnel.

Morgan Stanley Research personnel may participate in company events such as site visits and are generally prohibited from accepting payment by the company of associated expenses unless pre-approved by authorized members of Research management.

Morgan Stanley may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

To our readers in Taiwan: Information on securities/instruments that trade in Taiwan is distributed by Morgan Stanley Taiwan Limited ("MSTL"). Such information is for your reference only. The reader should independently evaluate the investment risks and is solely responsible for their investment decisions. Morgan Stanley Research may not be distributed to the public media or quoted or used by the public media without the express written consent of Morgan Stanley. Information on securities/instruments that do not trade in Taiwan is for informational purposes only and is not to be construed as a recommendation or a solicitation to trade in such securities/instruments. MSTL may not execute transactions for clients in these securities/instruments. To our readers in Hong Kong: Information is distributed in Hong Kong by and on behalf of, and is attributable to, Morgan Stanley Asia Limited as part of its regulated activities in Hong Kong. If you have any queries concerning Morgan Stanley Research, please contact our Hong Kong sales representatives.

Morgan Stanley is not incorporated under PRC law and the research in relation to this report is conducted outside the PRC. Morgan Stanley Research does not constitute an offer to sell or the solicitation of an offer to buy any securities in the PRC. PRC investors shall have the relevant qualifications to invest in such securities and shall be responsible for obtaining all relevant approvals, licenses, verifications and/or registrations from the relevant governmental authorities themselves.

Morgan Stanley Research is disseminated in Brazil by Morgan Stanley S.A.; in Japan by Morgan Stanley MUFG Securities Co., Ltd. and, for Commodities related research reports only, Morgan Stanley Capital Group Japan Co., Ltd.; in Hong Kong by Morgan Stanley Asia Limited (which accepts responsibility for its contents) and by Bank Morgan Stanley AG, Hong Kong Branch; in Singapore by Morgan Stanley Asia (Singapore) Pte. (Registration number 199206298Z) and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H), regulated by the Monetary Authority of Singapore (which accepts legal responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research) and by Bank Morgan Stanley AG, Singapore Branch (Registration number T11FC0207F); in Australia to "wholesale clients" within the meaning of the Australian Corporations Act by Morgan Stanley Australia Limited (67 003 734 576, holder of Australian financial services license No. 233742, which accepts responsibility for its contents; in Australia to "wholesale clients" and "retail clients" within the meaning of the Australian Corporations Act by Morgan Stanley Wealth Management Australia Pty Ltd (19 009 145 555, holder of Australian financial services license No. 240813, which accepts responsibility for its contents; in Korea by Morgan Stanley & Co International plc, Seoul Branch; in India by Morgan Stanley India Company Private Limited; in Indonesia by PT Morgan Stanley Asia Indonesia; in Canada by Morgan Stanley Canada Limited, which has approved of and takes responsibility for its contents in Canada; in Germany by Morgan Stanley Bank AG, Frankfurt am Main and Morgan Stanley Private Wealth Management Limited, Niederlassung Deutschland, regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin); in Spain by Morgan Stanley, S.V., S.A., a Morgan Stanley group company, which is supervised by the Spanish Securities Markets Commission (CNMV) and states that Morgan Stanley Research has been written and distributed in accordance with the rules of conduct applicable to financial research as established under Spanish regulations; in the US by Morgan Stanley & Co. LLC, which accepts responsibility for its contents. Morgan Stanley & Co. International plc, authorized by the Prudential Regulatory Authority and regulated by the Financial Conduct Authority and the Prudential Regulatory Authority, disseminates in the UK research that it has prepared, and approves solely for the purposes of section 21 of the Financial Services and Markets Act 2000, research which has been prepared by any of its affiliates. Morgan Stanley Private Wealth Management Limited, authorized and regulated by the Financial Conduct Authority, also disseminates Morgan Stanley Research in the UK. Private UK investors should obtain the advice of their Morgan Stanley & Co. International plc or Morgan Stanley Private Wealth Management representative about the investments concerned. RMB Morgan Stanley (Proprietary) Limited is a member of the JSE Limited and regulated by the Financial Services Board in South Africa. RMB Morgan Stanley (Proprietary) Limited is a joint venture owned equally by Morgan Stanley International Holdings Inc. and RMB Investment Advisory (Proprietary) Limited, which is wholly owned by FirstRand Limited.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (DIFC Branch), regulated by the Dubai Financial Services Authority (the DFSA), and is directed at Professional Clients only, as defined by the DFSA. The financial products or financial services to which this research relates will only be made available to a customer who we are satisfied meets the regulatory criteria to be a Professional Client.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (QFC Branch), regulated by the Qatar Financial Centre Regulatory Authority (the QFCRA), and is directed at business customers and market counterparties only and is not intended for Retail Customers as defined by the QFCRA.

As required by the Capital Markets Board of Turkey, investment information, comments and recommendations stated here, are not within the scope of investment advisory activity. Investment advisory service is provided exclusively to persons based on their risk and income preferences by the authorized firms. Comments and recommendations stated here are general in nature. These opinions may not fit to your financial status, risk and return preferences. For this reason, to make an investment decision by relying solely to this information stated here may not bring about outcomes that fit your expectations.

The trademarks and service marks contained in Morgan Stanley Research are the property of their respective owners. Third-party data providers make no warranties or representations relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages relating to such data. The Global Industry Classification Standard (GICS) was developed by and is the exclusive property of MSCI and Morgan Stanley Research or portions of it may not be reprinted, sold or redistributed without the written consent of Morgan Stanley.

Morgan Stanley Research, or any portion thereof may not be reprinted, sold or redistributed without the written consent of Morgan Stanley.

The Americas

1585 Broadway
New York, NY 10036-8293
United States
Tel: +1 (1) 212 761 4000

Europe

20 Bank Street, Canary Wharf
London E14 4AD
United Kingdom
Tel: +44 (0) 20 7 425 8000

Japan

1-9-7 Otemachi, Chiyoda-ku
Tokyo 100-8104
Japan
Tel: +81 (0) 3 6836 5000

Asia/Pacific

1 Austin Road West
Kowloon
Hong Kong
Tel: +852 2848 5200

Industry Coverage:Biotechnology

Company (Ticker)	Rating (as of)	Price* (07/23/2014)
------------------	----------------	---------------------

David Friedman, ■■■		
AMAG Pharmaceuticals, Inc. (AMAG.O)	E (11/21/2011)	\$19.04
Akebia Therapeutics Inc (AKBA.O)	O (04/14/2014)	\$23.19
Alexion Pharmaceuticals (ALXN.O)	O (09/07/2010)	\$173.08
Alnylam Pharmaceuticals (ALNY.O)	E (01/14/2014)	\$55.86
Auxilium Pharmaceuticals (AUXL.O)	U (03/06/2014)	\$19.6
Chimerix Inc (CMRX.O)	O (05/06/2013)	\$22.87
Cubist Pharmaceuticals Inc. (CBST.O)	O (11/13/2013)	\$62.58
GW Pharmaceuticals PLC (GWPH.O)	O (04/22/2014)	\$86.68
Idenix Pharmaceuticals, Inc. (IDIX.O)	E (03/18/2011)	\$24.32
Incyte Corporation (INCY.O)	U (01/23/2013)	\$48.98
InterMune (ITMN.O)	E (09/07/2010)	\$46.4
Ironwood Pharmaceuticals, Inc. (IRWD.O)	E (04/24/2013)	\$15.05
Lexicon Pharmaceuticals, Inc. (LXRX.O)	U (06/11/2013)	\$1.59
NPS Pharmaceuticals (NPSP.O)	++	\$29.33
Neurocrine Biosciences Inc (NBIX.O)	E (01/08/2014)	\$13.71
Ophthotech Corp (OPHT.O)	O (10/21/2013)	\$40.63
Portola Pharmaceuticals Inc (PTLA.O)	O (06/17/2013)	\$24.92
Rellypsa, Inc. (RLYP.O)	O (12/10/2013)	\$24.98
Synageva Biopharma Corp (GEVA.O)	O (04/20/2012)	\$72.44
Theravance Inc (THRX.O)	U (07/22/2013)	\$25.32
Ultragenyx Pharmaceutical Inc (RARE.O)	O (02/25/2014)	\$43.05
Versartis, Inc. (VSAR.O)	O (04/15/2014)	\$23.45
Vertex Pharmaceuticals (VRTX.O)	E (05/08/2012)	\$98.14
XenoPort Inc (XNPT.O)	U (06/11/2013)	\$4.39
Matthew Harrison		
Amgen Inc. (AMGN.O)	O (03/26/2014)	\$122.01
Biogen Idec Inc. (BIIB.O)	O (03/26/2014)	\$337.6
Celgene Corp (CELG.O)	E (03/26/2014)	\$89.12
Gilead Sciences Inc. (GILD.O)	E (03/26/2014)	\$90.34
ImmunoGen Inc. (IMGN.O)	U (06/25/2014)	\$11.38
Infinity Pharmaceuticals Inc (INFI.O)	O (06/25/2014)	\$9.82

Pharmacycics Inc. (PCYC.O)	E (03/26/2014)	\$103.92
Regeneron Pharmaceuticals Inc. (REGN.O)	E (03/26/2014)	\$310.27

Stock Ratings are subject to change. Please see latest research for each company.
* Historical prices are not split adjusted.